Protection assessments indicated that gastrointestinal adverse situations, primarily nausea and diarrhea, were dose-dependent but typically mild and transient. These findings founded the therapeutic window and educated dose variety for subsequent Phase 3 trials.Renal elimination of unchanged orforglipron is small, with excretion occurring l… Read More